FINWIRES · TerminalLIVE
FINWIRES

$CLYM

13 stories mentioning CLYMUpdated 18d ago

Every FINWIRES story that references CLYM, newest first.

What are analysts saying about CLYM?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on CLYM?

Wire

Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says

Climb Bio's (CLYM) data from the first phase of its trial evaluating CLYM116 in patients with IgA nephropathy was "positive," Wedbush analysts said in a Friday note.Analysts said they see favorable risk/reward for Climb Bio's shares as additional phase 1 data will likely be presented at the American Society of Nephrology.Some investors were looking for a more clear-cut "winner" between Climb Bio and Jade Biosciences (JBIO) in their nephropathy clinical trials, Wedbush said.Analysts said they expect the valuation gap between Climb Bio and Jade Biosciences to narrow over time as both agents offer benefits compared with first-gen agents.Wedbush kept its outperform rating and a $25 price target on the stock.Shares of the company were up nearly 8% in Friday trading.Price: $15.75, Change: $+1.16, Percent Change: +7.95%

$CLYM$JBIO
Wire

Update: Climb Bio Shares Fall After Early Phase 1 Data for IgA Nephropathy Drug

(Updates with the company's stock move in the headline and the first paragraph.)Climb Bio (CLYM) shares were down 3.7% in Thursday trading after its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.Price: $14.50, Change: $-0.55, Percent Change: -3.65%

$CLYM
Wire

Wedbush Adjusts Price Target on Climb Bio to $25 From $20, Keeps Outperform Rating

Climb Bio (CLYM) has an average rating of buy and mean price target of $24.40, according to analysts polled by FactSet.Price: $14.37, Change: $-0.69, Percent Change: -4.55%

$CLYM
Wire

Climb Bio's CLYM116 Data Could Show Competitive Position in IgA Nephropathy Market, Oppenheimer Says

Climb Bio's (CLYM) CLYM116 could stand out in the growing IgA nephropathy treatment market if Thursday's phase 1 data shows strong and lasting APRIL and IgA reductions that support less frequent dosing, Oppenheimer said in a note Wednesday.The key question for Thursday's results is whether CLYM116 can deliver strong and durable effects that could support an infrequently administered under-the-skin treatment, Oppenheimer said.The investment firm said other approved and experimental anti-APRIL drugs have already shown that targeting APRIL can work in IgAN, setting a benchmark for CLYM116.The phase 2 portion of partner Mabworks' phase 1/2 IgAN study is expected to begin before the end of the quarter, with Climb Bio planning to present additional CLYM116 data at a medical meeting in Q4, the firm noted.Oppenheimer kept its outperform rating and $18 price target for Climb Bio.Price: $14.62, Change: $-0.21, Percent Change: -1.38%

$CLYM
Wire

Climb Bio's Upcoming CLYM116 Data Could Support Longer Dosing, Strong Potency, Oppenheimer Says

Climb Bio's (CLYM) upcoming CLYM116 data could show strong drug activity, longer-lasting effects and potential dosing every eight to 12 weeks, which would strengthen the drug's position against rivals, Oppenheimer said in a note Monday.The investment firm said it expects Thursday's phase 1 update to show how different doses affect IgA levels and how long the treatment effect lasts.A 60% to 70% drop in IgA at relatively low doses would support its view that CLYM116 may be more potent than competing drugs, Oppenheimer said.CLYM116 may also provide longer-lasting effects by clearing the APRIL protein more effectively, while its ability to use higher doses could further extend the treatment benefit, according to the note.Oppenheimer has an outperform rating and $18 price target for Climb Bio.Price: $14.17, Change: $-0.40, Percent Change: -2.75%

$CLYM
Wire

Climb Bio Offers Compelling, Data-Rich H2 With Multiple Near-term Catalysts Across Two Programs, RBC Says

Climb Bio (CLYM) offers a compelling, data-rich H2, with several near-term catalysts across two differentiated programs in highly unmet need B-cell mediated diseases, RBC Capital Markets said in a Monday research note.RBC said that the proof-of-concept data for the company's Budoprutug anti-CD19 monoclonal antibody in primary membranous nephropathy from low dose has demonstrated early signals of efficacy, with recent immune thrombocytopenia data further de-risking the safety profile, suggesting Budoprutug can be dosed even higher.RBC said it sees out-year sales of about $700 million from Budoprutug across indications of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.RBC further said that the company's "CLYM116 anti-APRIL mechanism is de-risked" reflecting clinical and commercial validation, with sweeper Fc engineering potentially placing it competitively in the crowded IgA nephropathy market.RBC initiated its coverage on the company's stock with an outperform rating and $23 per share price target.Price: $11.40, Change: $-0.50, Percent Change: -4.20%

$CLYM
Research

RBC Capital Initiates Climb Bio at Outperform With $23 Price Target

Climb Bio (CLYM) has an average rating of buy and mean price target of $21.27, according to analysts polled by FactSet.

$CLYM
Insider Trading

Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing

Aoife Brennan, Director, President and Chief Executive Officer, on June 27, 2026, sold 30,902 shares in Climb Bio (CLYM) for $406,979. Following the Form 4 filing with the SEC, Brennan has control over a total of 87,731 common shares of the company, with 87,731 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1768446/000119312526291131/xslF345X05/ownership.xml

$CLYM
Research

Guggenheim Initiates Climb Bio at Buy With $35 Price Target

Climb Bio (CLYM) has an average rating of buy and mean price target of $19.77, according to analysts polled by FactSet.

$CLYM
Wire

Wedbush Adjusts Price Target on Climb Bio to $15 From $14, Maintains Outperform Rating

Climb Bio (CLYM) has an average rating of buy and mean price target of $18.69, according to analysts polled by FactSet.Price: $11.98, Change: $+0.53, Percent Change: +4.63%

$CLYM
Research

Chardan Initiates Climb Bio at Buy With $22 Price Target

Climb Bio (CLYM) has an average rating of buy and mean price target of $16.69, according to analysts polled by FactSet.

$CLYM
Wire

Climb Bio Sees Upgraded Outlook on Strong IgAN Drug Development Pipeline, Oppenheimer Says

Climb Bio (CLYM) is drawing increased analyst optimism following updated expectations for its immunology pipeline, particularly its investigational therapies for IgA nephropathy, Oppenheimer said in a Tuesday note.Oppenheimer highlighted growing confidence in Climb Bio's anti-APRIL programs, including CLYM116, citing potential best-in-class efficacy, stronger-than-expected proteinuria reduction, longer dosing intervals, and a favorable safety profile as key differentiators.According to the report, upcoming clinical readouts for subcutaneous budoprutug and CLYM116 could serve as key catalysts, potentially validating Climb Bio's IgAN approach, with strong pricing dynamics supporting commercial upside if results are positive.Oppenheimer maintained its outperform rating on the stock and raised its price target to $18 from $10.Shares of Climb Bio were up more than 6% in Tuesday trading.Price: $9.49, Change: $+0.52, Percent Change: +5.80%

$CLYM
Research

Mizuho Initiates Climb Bio at Outperform With $18 Price Target

Climb Bio (CLYM) has an average rating of buy and mean price target of $15.58, according to analysts polled by FactSet.

$CLYM

Track with the FINWIRES app suite

FolioX
FolioX
Track CLYM in your portfolio
WheelAI
WheelAI
Analyze CLYM options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CLYM